Comparison
Buserelin vs. Glepaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
57982-77-1
no data
Molecular weight
1239.42 g/mol
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
1
of which in humans
0
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Buserelin and Glepaglutide?
- Buserelin is classified as "Research other", while Glepaglutide is classified as "Research other". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or Glepaglutide?
- The highest available evidence level is "Human RCT" for Buserelin and "Human RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and Glepaglutide in Germany and the United States?
- Germany: Buserelin — Prescription, Glepaglutide — Unapproved. United States: Buserelin — Unapproved, Glepaglutide — Unapproved. These are factual summaries with source and review date on the individual pages.